Charles Explorer logo
🇬🇧

The fastest insulin in the world

Publication at Faculty of Medicine in Hradec Králové |
2018

Abstract

An insulin analog FiAsp with the ability to reduce postprandial blood glucose more quickly reduces the time difference between the response of endogenous and exogenous insulin and brings diabetes to a healthy human being. Patients can more easily correct postprandial hyperglycemia, which accounts for a significant proportion of total hyperglycemia, expressed as glycated hemoglobin.

At the same time, the risk of microvascular and macrovascular complications is reduced. The new ultra-short FiAsp analog improved the safety of postrandial blood glucose in randomized trials in patients with type 1 and type 2 diabetes, both in subcutaneous injection and insulin pumps.